Stocks Health care XENE
NASDAQ · Health careXenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. brought in $0 of revenue over the twelve months to June 30, 2026, down 100.0% from a year earlier. It posted a net loss of $409.2M. In fiscal 2025 capital spending exceeded operating cash flow by $279.9M. At June 30, 2026 it held $119.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Xenon Pharmaceuticals Inc. does
Xenon Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XENE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.5M | -$345.9M | -$4.36 | -$279.9M |
| 2024 | $0 | -$234.3M | -$3.01 | -$184.5M |
| 2023 | $0 | -$182.4M | -$2.73 | -$156.7M |
| 2022 | $9.4M | -$125.4M | -$2.06 | -$103.9M |
| 2021 | $18.4M | -$78.9M | -$1.77 | -$71.6M |
| 2020 | $32.2M | -$28.8M | -$0.81 | -$50.8M |
Latest SEC filings
What Xenon Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- June 3, 2026Form S-8 POS filing S-8 POS
- June 3, 2026Form S-8 POS filing S-8 POS
- June 3, 2026Form S-8 POS filing S-8 POS
- June 3, 2026Form S-8 POS filing S-8 POS
- June 3, 2026Form S-8 POS filing S-8 POS
Questions about XENE
What does Xenon Pharmaceuticals Inc. do?
Xenon Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XENE.
Is Xenon Pharmaceuticals Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $409.2M.
How much revenue does Xenon Pharmaceuticals Inc. make?
Over the twelve months to June 30, 2026 Xenon Pharmaceuticals Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Xenon Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
Similar companies
Follow XENE
Get an email when Xenon Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow XENE: get an email when it filesWhere the numbers come from
Financial figures are the values Xenon Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.